Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TG 4010

Drug Profile

TG 4010

Alternative Names: Cancer vaccine - Transgene; MVA-MUC1-IL2; TG-4010

Latest Information Update: 29 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene
  • Developer Bristol-Myers Squibb; Transgene; University of California, Davis
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Interleukin 12 stimulants; Mucin 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Suspended Prostate cancer; Renal cell carcinoma
  • Discontinued Breast cancer

Most Recent Events

  • 28 May 2019 Transgene completes enrolment in its phase II trial for Non-Small cell lung cancer (Late-stage disease; Combination-therapy; Second-line therapy or greater) in USA, Belgium, Denmark, France and Hungary
  • 23 Jan 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in Denmark (SC) (EudraCT2016-005115-41)
  • 16 Jan 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (SC) (NCT03353675)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top